^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DPX-E7

    i
    Other names: DPX-E7, DPX E7, HPV16-E711-19
    Associations

    News

    Trials
    Company:
    BioVaxys
    Drug class:
    HPV-16 E7 protein inhibitor, Viral protein inhibitor
    Related drugs:
    Associations

    News

    Trials
    24d
    E711-19 placement and orientation dictate CD8+ T cell response in structurally defined spherical nucleic acid vaccines. (PubMed, Sci Adv)
    Herein, three SNAs were designed with HLA-A2-restricted HPV16 E711-19 peptide and CpG adjuvant, nearly identical in composition but differing in antigen presentation...Transcriptomic profiling revealed up-regulation of activation genes and suppression of exhaustion markers. In patient-derived HPV+ head and neck cancer spheroids, N-HSNA enhanced cytotoxicity ~2.5-fold, establishing antigen placement and orientation as key parameters for translational cancer immunotherapy.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
    |
    DPX-E7
    2years
    Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer (clinicaltrials.gov)
    P1/2, N=11, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Feb 2023
    Trial completion • Trial completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02 • HLA-A2 positive
    |
    cyclophosphamide • DPX-E7
    4years
    Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer (clinicaltrials.gov)
    P1/2, N=11, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
    Trial completion date • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02 • HLA-A2 positive
    |
    DPX-E7
    over4years
    Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer (clinicaltrials.gov)
    P1/2, N=11, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Dec 2020 --> Dec 2021
    Clinical • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A2 positive • HLA-A*02 positive
    |
    DPX-E7